Seattle Genetics Inc. announced encouraging data from Phase II clinical trials for ADCETRIS in patients with relapsed/refractory and frontline diffuse large B-cell lymphoma, or DLBCL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma, anaplastic large cell lymphoma and several other types of non-Hodgkin lymphoma. The activity observed supports plans to initiate a randomized Phase II clinical trial of ADCETRIS for relapsed CD30-positive DLBCL patients during 2015 and to pursue possible frontline DLBCL combination trials." An ongoing Phase II clinical trial in relapsed or refractory DLBCL includes three treatment arms to evaluate ADCETRIS in CD30-positive disease, CD30-undetectable disease and in combination with Rituxan (rituximab).